Shikonin ameliorates renal fibrosis by targeting HSPA1A to regulate lipid metabolism and inhibit ferroptosis
Phytomedicine · 2026-03 · 152 · 157882
DOI: 10.1016/j.phymed.2026.157882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026-03. Verfasst von Zhirui Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, Anhui Pro…. Hauptthemen laut MEDLINE: Naphthoquinones, Ferroptosis, Lipid Metabolism, HSP70 Heat-Shock Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Wannan Medical College, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Renal fibrosis (RF) is a critical step in the progression of chronic kidney disease to end-stage renal failure, but its treatment remains highly challenging, highlighting the urgent clinical need for novel therapeutic strategies. Shikonin, a naturally derived compound, shows promise in attenuating the progression of RF. A thorough understanding of its specific molecular targets and mechanism of action is essential. PURPOSE: This study elucidates the molecular mechanism through which Shikonin modulates HSPA1A to suppress ferroptosis and regulate lipid metabolism in RF. METHODS: A unilateral ureteral obstruction (UUO) mouse model was used to assess the antifibrotic effects of Shikonin. Efficacy was evaluated by analyzing renal pathomorphological changes and fibrosis indicators, and by using ELISA to detect the inflammation levels and kidney function. We integrated results from network pharmacology, transcriptomics, and non-targeted metabolomics to explore Shikonin's mechanism in renal fibrosis and verified it through experiments including qRT-PCR, immunofluorescence, western blot, transmission electron microscopy, ROS staining, and Bodipy staining. In vitro, human renal tubule epithelial cells (HK-2) were stimulated with TGF-β1 and then treated with Shikonin. Lipid-MS, CETSA, SPR, and molecular dynamics simulations were jointly employed to identify Shikonin's target. After knocking down this target in vivo using AAV, the effect of Shikonin on renal fibrosis was observed. RESULTS: Shikonin notably ameliorated histopathological lesions, renal dysfunction, pathological damage and fibrosis in UUO model. Transcriptomic and non-targeted metabolomics analyses indicated that lipid metabolism specifically the arachidonic acid (AA) pathway, is a key pathway through which Shikonin exerted its effects. Mechanistically, Shikonin directly bind to HSPA1A and, through this interaction, downregulated the expression of key AA-metabolizing enzymes ACSL4 and ALOX15, thereby suppressing lipid peroxidation and ferroptosis. This mechanism was confirmed both in vivo and in vitro. Crucially, the anti-fibrosis efficacy of Shikonin was abolished upon HSPA1A knockdown or inhibition, and could be functionally reversed by exogenous AA supplementation. CONCLUSION: This study has revealed a novel mechanism by which Shikonin alleviates renal fibrosis: by targeting HSPA1A to reprogram AA metabolism and inhibit ferroptosis. These findings display the HSPA1A-AA metabolism-ferroptosis axis as a critical therapeutic pathway and provide a compelling mechanistic foundation for developing Shikonin as a promising candidate drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, Anhui Province, China; Department of Pharmacy, Wannan Medical College, Wuhu 241…
- Department of Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
- Key Laboratory of Exploitation and Study of Distinctive Plants in Education Department of Sichuan Province, Sichuan University of Arts and Science, Dazhou 635000, China.
- Department of pathology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, Anhui Province, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, Anhui Province, China.
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China. Electronic address: zyj@ahmu.edu.cn.
Förderung
- Wannan Medical College
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Z., Zhang, M., Chen, L., Xu, W., Xu, H., Zou, S., Wang, T., Wang, L., Zhao, Y., & Jiao, H. (2026). Shikonin ameliorates renal fibrosis by targeting HSPA1A to regulate lipid metabolism and inhibit ferroptosis. Phytomedicine, 152, 157882. https://doi.org/10.1016/j.phymed.2026.157882
Vancouver
Zhang Z, Zhang M, Chen L, Xu W, Xu H, Zou S, et al. Shikonin ameliorates renal fibrosis by targeting HSPA1A to regulate lipid metabolism and inhibit ferroptosis. Phytomedicine. 2026;152:157882. doi:10.1016/j.phymed.2026.157882
BibTeX
@article{Zhang2026,
author = {Zhang, Zhirui and Zhang, Meijuan and Chen, Lili and Xu, Wuqin and Xu, Huifang and Zou, Songsong and Wang, Tao and Wang, Lin and Zhao, Yingjie and Jiao, Hao},
title = {Shikonin ameliorates renal fibrosis by targeting HSPA1A to regulate lipid metabolism and inhibit ferroptosis},
journal = {Phytomedicine},
year = {2026},
volume = {152},
pages = {157882},
doi = {10.1016/j.phymed.2026.157882}
}
EUVIMED